Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476770 · ClinicalTrials.gov registry record · Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
A Phase 1 study of Hodgkin Lymphoma and Hematologic Malignancy, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 20
- Study locations
NCT05476770 is a Phase 1 study of Hodgkin Lymphoma and Hematologic Malignancy that is actively recruiting participants, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 54 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05476770, a Phase 1 study of Hodgkin Lymphoma and Hematologic Malignancy, is actively recruiting participants, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 20
- Study locations
Study Summary
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Cytarabine
- DRUG Tagraxofusp
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital Orange County - Orange
- UCSF School of Medicine - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Rainbow Babies - Cleveland
- Nationwide Children's Hospital - Columbus
Maryland
- Johns Hopkins University - Baltimore
- National Cancer Institute, Pediatric Oncology Branch - Bethesda
New York
- Children's Hospital New York-Presbyterian - New York
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Children's Hospital Colorado - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of Miami - Miami
Georgia
- Children's Healthcare of Atlanta, Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2027-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476770
The ClinicalTrials.gov registry entry for NCT05476770 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower). The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT05476770 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Maryland.
Frequently Asked Questions
What is clinical trial NCT05476770 about?
NCT05476770 is a clinical study titled "Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies". Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patien...
What is the current status of trial NCT05476770?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2022-11-11. Estimated completion is 2027-11-11.
What conditions does trial NCT05476770 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma, Hematologic Malignancy, Lymphoma, B-Cell, Mixed Phenotype Acute Leukemia, AML.
What interventions are being tested in trial NCT05476770?
The interventions under investigation include: Fludarabine (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Cytarabine (DRUG), Tagraxofusp (DRUG).
Who is sponsoring clinical trial NCT05476770?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05476770 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.